XmAb18968 (CD3-CD38) in Relapsed or Refractory Acute Leukemia and T Cell Lymphoblastic Leukemia

NCT05038644 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

22

Enrollment

OTHER

Sponsor class

Stopped Drug expired May 31, 2024.

Conditions

Acute Myeloid Leukemia
T Cell Acute Lymphoblastic Leukemia
T Cell Lymphoblastic Lymphoma

Interventions

DRUG: XmAb18968 - Dose level -1
DRUG: XmAb18968 - Dose level 0 (starting dose)
DRUG: XmAb18968 - Dose level 1
DRUG: XmAb18968 - Dose level 2
DRUG: XmAb18968 - Dose level 3

Sponsor

Ehab L Atallah